Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to OSU, City of Hope, Alnylam, and More


Title: microRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors

Patent Number: 8,389,210

Filed: Feb. 4, 2010

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent’s abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.”

Title: Methods and Kits for Synthesis

Patent Number: 8,389,244

Filed: July 31, 2003

Lead Inventor: John Rossi, City of Hope

The patent, its abstract states, claims “amplification-based methods and kits for rapidly producing siRNA expression cassettes. … Also provided are methods for expressing amplified siRNA expression cassettes in cells.”

Title: Encapsulated Nanoparticles for Nucleic Acid Delivery

Patent Number: 8,389,485

Filed: Oct. 29, 2008

Lead Inventor: Michael Czech, University of Massachusetts

The invention, the patent’s abstract states, comprises “methods and compositions for delivering agents and molecules to cells using yeast cell wall particles. ... Embodiments of the invention are particularly useful for the delivery of nucleic acids to cells.”

Title: siRNA-Mediated Gene Silencing of Synuclein

Patent Number: 8,389,487

Filed: Jan. 25, 2010

Lead Inventor: Martha Bohn, Children's Hospital of Chicago

The invention relates to “small interfering RNAs that down-regulate expression of a synuclein gene and methods of using the small interfering RNAs,” the patent’s abstract states.

Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure

Patent Number: 8,389,490

Filed: Sept. 2, 2010

Lead Inventor: Ana Jimenez, Sylentis

The invention, the patent’s abstract states, “relates to methods and compositions that decrease intraocular pressure of the eye. The compositions of the invention comprise short interfering nucleic acid molecules … that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased [intraocular pressure] such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.”

Title: Method of Cancer Treatment Using siRNA Silencing

Patent Number: 8,389,708

Filed: July 25, 2008

Inventor: Weiping Min, University of Western Ontario

The invention, the patent’s abstract states, relates to a “method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.”

Title: Compositions and Methods for Treating Tumors, Fibrosis, and Pulmonary Alveolar Proteinosis

Patent Number: 8,389,709

Filed: July 15, 2008

Inventor: Gera Neufeld, Israel Institute of Technology

The patent, its abstract states, claims “pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.”

Title: Humanized Lewis-Y-Specific Antibody-Based Delivery of Dice-Substrate siRNA against STAT3

Application Number: 20130052731

Filed: March 19, 2012

Lead Inventor: Yuelog Ma, City of Hope

The invention, the patent application’s abstract states, relates to “methods for covalently or non-covalently conjugating an antibody or functional fragment thereof with an siRNA molecule.”

Title: Monomers and Oligonucleotides Comprising Cycloaddition Adducts

Application Number: 20130053334

Filed: Jan. 28, 2011

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent application’s abstract states, relates to “compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.”